Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 1 | 1 | 3 | 0 | 0 |
Analyst Firms Making Recommendations1
- Wells Fargo
- Stifel
- LifeSci Capital
- JonesTrading
- HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aeglea BioTherapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/16/2023 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -95.79% | Wells Fargo | Yanan Zhu | $8.75 → $12.5 | Maintains | Equal-Weight | Get Alert |
| 07/25/2023 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -92.42% | Stifel | Alex Thompson | → $22.5 | Initiates | → Buy | Get Alert |
| 04/12/2023 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | — | LifeSci Capital | Sam Slutsky | — | Downgrade | Outperform → Market Perform | Get Alert |
| 04/12/2023 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | — | JonesTrading | Soumit Roy | — | Downgrade | Buy → Hold | Get Alert |
| 03/03/2023 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -91.58% | HC Wainwright & Co. | Edward White | → $25 | Maintains | Neutral | Get Alert |
| 10/28/2022 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -83.16% | Wells Fargo | Yanan Zhu | $37.5 → $50 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 08/09/2022 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -87.37% | Wells Fargo | Yanan Zhu | $50 → $37.5 | Maintains | Equal-Weight | Get Alert |
| 06/03/2022 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | — | Needham | Gil Blum | — | Downgrade | Buy → Hold | Get Alert |
| 06/03/2022 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -91.58% | HC Wainwright & Co. | Edward White | $425 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 05/23/2022 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -66.33% | Piper Sandler | Edward Tenthoff | $175 → $100 | Maintains | Overweight | Get Alert |
| 05/06/2022 | AGLE | Buy Now | Aeglea BioTherapeutics | $11.88 | -24.24% | Needham | Gil Blum | $300 → $225 | Maintains | Buy | Get Alert |
What is the target price for Aeglea BioTherapeutics (AGLE)?
The latest price target for Aeglea BioTherapeutics (NASDAQ: AGLE) was reported by Wells Fargo on August 16, 2023. The analyst firm set a price target for $0.50 expecting AGLE to fall to within 12 months (a possible -95.79% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aeglea BioTherapeutics (AGLE)?
The latest analyst rating for Aeglea BioTherapeutics (NASDAQ: AGLE) was provided by Wells Fargo, and Aeglea BioTherapeutics maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Aeglea BioTherapeutics (AGLE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aeglea BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aeglea BioTherapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating Aeglea BioTherapeutics (AGLE) correct?
While ratings are subjective and will change, the latest Aeglea BioTherapeutics (AGLE) rating was a maintained with a price target of $0.35 to $0.50. The current price Aeglea BioTherapeutics (AGLE) is trading at is $11.88, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.